Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine
11 nov. 2023 08h31 HE
|
Novo Nordisk A/S
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity...
COMPASS Prequalification Tool launches the 2022 COMPASS Select List
06 déc. 2022 11h07 HE
|
Bespoke Metrics
TORONTO, Dec. 06, 2022 (GLOBE NEWSWIRE) -- COMPASS, by Bespoke Metrics, has released its inaugural COMPASS Select List. This list recognizes the top subcontractors in the COMPASS Prequalification...
NUVERRA ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of NES and Encourages Investors to Contact the Firm
14 déc. 2021 12h44 HE
|
Bragar Eagel & Squire
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors...
Jounce Therapeutics Announces Update on Vopratelimab Program
02 nov. 2020 07h00 HE
|
Jounce Therapeutics, Inc.
- No further enrollment in EMERGE trial of vopratelimab in combination with ipilimumab based on interim analysis- - First patient dosed in SELECT trial of vopratelimab in combination with JTX-4014 in...
Jounce Therapeutics Reports Second Quarter 2020 Financial Results
07 août 2020 06h30 HE
|
Jounce Therapeutics, Inc.
- Completed enrollment of Phase 2 EMERGE trial for the interim analysis of efficacy and biomarker data in early 2021 - - On track to initiate Phase 2 SELECT trial and Phase 1 trial for JTX-8064 in...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
27 févr. 2020 06h30 HE
|
Jounce Therapeutics, Inc.
- On track to initiate Phase 2 SELECT trial in mid-2020 and present preliminary efficacy and related biomarker data from Phase 2 EMERGE trial in 2H 2020 - - Ended 2019 with $170.4 million in...
Jounce Therapeutics Presents New Vopratelimab Predictive Biomarker Data Supporting Use in the Upcoming SELECT Trial at the 2020 ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting and Announces Research Collaboration with NanoString Technologies
06 févr. 2020 08h00 HE
|
Jounce Therapeutics, Inc.
- Identification of a predictive biomarker – based on an 18 gene RNA signature and vopratelimab-specific threshold (TISvopra) – for the emergence of ICOS hi CD4 T cells that predicted clinical benefit...
PRIVATE BLACK CARD COMMUNITY ‘SELECT’ LAUNCHES ALL-NEW ‘SELECT HOTELS’ BOOKING PROGRAM
07 sept. 2016 08h25 HE
|
SELECT
New York, NY, Sept. 07, 2016 (GLOBE NEWSWIRE) -- SELECT, the preeminent black card and concierge service, announced the launch of their all-new SELECT HOTELS Travel Program. The first-of-its-kind...
FoodFan, Inc. Launches Exclusive Discount Program, Select
08 août 2013 11h07 HE
|
FoodFan Inc.
NEW YORK, Aug. 8, 2013 (GLOBE NEWSWIRE) -- FoodFan Inc. - the social destination for discovering and sharing restaurants - launched Select, the first exclusive membership program that lets diners save...